- Cannabis Drug Shows Promise in Treating Schizophrenia
- CBDas an antipsychotic drug
- Cannabidiol as a potential treatment for psychosis
- CBDenhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- Medical use of cannabis. CBD: A new light for schizophrenia?
- A critical review of the antipsychotic effects of CBD: 30 years of a translational investigation
- Peripheral endocannabinoid system dysregulation in first-episode psychosis
- Cannabinoids and schizophrenia
- Antipsychotic-like effects of cannabidiol and rimonabant
- CBDmonotherapy for treatment-resistant schizophrenia
- Cannabis with high CBDcontent is associated with fewer psychotic experiences
- Marijuana compound treats schizophrenia with few side effects: Clinical trial
- Clearing the smoke: what do we know about adolescent cannabis use and schizophrenia?
- Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments
- Improved Social Interaction, Recognition and Working Memory with CBDTreatment in a Prenatal Infection Rat Model.
Medical Research on CBD (cannabidiol)
Clinical studies and case reports on CBD categorized by condition:
- General Research Acne ADD - ADHD Addiction AIDS ALS Alzheimers Anorexia Antibiotic Resistance Anxiety Arthritis Asthma Atherosclerosis Autism ASD Bipolar Disorder Cancer Chronic Pain Depression Diabetes Digestive Issues Endocrine Disorders Epilepsy - Seizures Fibromyalgia Glaucoma Heart Disease Huntington's Disease Inflammation Irritable Bowel Syndrome Liver Disease Metabolic Syndrome Migraines Mood Disorders Motion Sickness Multiple Sclerosis (MS) Nausea Neurodegeneration Obesity OCD Osteoporosis Parkinson's Disease PTSD Rheumatism Schizophrenia Sickle Cell Anemia Skin Conditions Sleep Disorders Stress Strokes